$SUPN good interim data

Supernus Pharmaceuticals (SUPN) came out with good interim data from a phase 3 study of SPN-810 for the treatment of impulsive aggression (IA) in children 6 - 12 years old. More news in our daily pharma scoop in our SeekingAlpha Marketplace page.